You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : HEALTHCARE EQUIPMENT & SUPPLIES
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. X.T.L. BIOPHARMACEUTICALS LTD. - ADR

X.T.L. Biopharmaceuticals Ltd. - ADR XNAS: XTLB

X.T.L. Biopharmaceuticals Ltd. - ADR Live Share Price Today, Share Analysis and Chart

Download real time

1.49 0.19 (14.62%)

52.70% Fall from 52W High

2,108 XNAS Volume

XNAS 25 Apr, 2025 2:57 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for X.T.L. Biopharmaceuticals Ltd. - ADR is on 30 Apr 2025 for the purpose of XTL Biopharmaceuticals Ltd Fourth Quarter Earnings Results for 2024 See details

X.T.L. Biopharmaceuticals ... Key Metrics

Select

Market Capitalization

Low in industry
13.1

PE TTM

Negative PE TTM
-12.4

PEG TTM

Negative PEG TTM
-0.2

Price to Book

Below industry Median
2.3

Institutional holding current Qtr %

Low in industry
2.6

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-157.2

Net Profit TTM Growth %

High in industry
53

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-471.6

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-963

Rel Perf vs Sector quarter%

-11.7

ROE Annual %

Negative ROE Annual %
-57.3

RoA Annual %

Negative RoA Annual %
-53.9
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
10.2 / 100
Momentum Score
Technically Bearish
32.7 / 100
Analyst Price Target
No estimates available

15

S

7

W

0

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


X.T.L. Biopharmaceuticals ... Live Price Chart

Switch to TradingView
Fetching data ...

X.T.L. Biopharmaceuticals ... Stock Analysis

X.T.L. Biopharmaceuticals ... stock analysis with key metrics, changes, and trends.

X.T.L. Biopharmaceuticals ... MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$1.78 M20.66%positive

Annual Net Profit rose 20.66% in the last year to $1.78 M. Its sector's average net profit growth for the last fiscal year was 6%.

Price to Earning Ratio-12.44-negative

Price to Earning Ratio is -12.44, which is negative.

Stock Price$1.49-41.8%negative

Stock Price fell 41.8% and underperformed its sector by 49.63% in the past year.

Quarterly Net profit$0.55 M157.21%negative

Quarterly Net profit fell 157.21% YoY to $0.55 M. Its sector's average net profit growth YoY for the quarter was 37.15%.

Return on Equity(ROE)-57.31 %-57.31%negative

Return on Equity(ROE) for the last financial year was -57.31%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.10 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0.1%.

Institutional Holding2.59 %0%neutral

Institutional Holding remained the same in the last quarter at 2.59%.

VIEW LESS


Loading data..

X.T.L. Biopharmaceuticals Ltd. - ADR - Company Profile

What does X.T.L. Biopharmaceuticals Ltd. - ADR do?

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

X.T.L. Biopharmaceuticals Ltd. - ADR Management structure

All Gross Remunerations are in USD
Mr. Shlomo Shalev
Chief Executive Officer and Director
-
2023
Gross Remuneration
Year
Mr. Itay Weinstein
Chief Financial Officer
-
2023
Gross Remuneration
Year

X.T.L. Biopharmaceuticals Ltd. - ADR Board of directors

All Gross Remunerations are in USD
Mr. Doron Turgeman
Chairman of the Board
-
2023
Gross Remuneration
Year
Mr. Shlomo Shalev
Chief Executive Officer and Director
-
2023
Gross Remuneration
Year
Ms. Osnat Hillel Fain
Independent Director
-
2023
Gross Remuneration
Year
Dr. Jonathan Schapiro
Director
-
2023
Gross Remuneration
Year
Dr. Dobroslav Melamed
Independent Director
-
2023
Gross Remuneration
Year
Mr. Alexander Rabinovich
Director
-
2023
Gross Remuneration
Year

X.T.L. Biopharmaceuticals Ltd. - ADR FAQ

How is X.T.L. Biopharmaceuticals Ltd. - ADR today?
X.T.L. Biopharmaceuticals Ltd. - ADR today is trading in the green, and is up by 14.62% at 1.49.
X.T.L. Biopharmaceuticals Ltd. - ADR is currently trading up 14.62% on an intraday basis. In the past week the stock rose 31.86%. stock has been down -19.46% in the past quarter and fell -41.80% in the past year. You can view this in the overview section.